Evotec SE (EVO)
EVO Stock Price Chart
Explore Evotec SE interactive price chart. Choose custom timeframes to analyze EVO price movements and trends.
EVO Company Profile
Discover essential business fundamentals and corporate details for Evotec SE (EVO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
5 Feb 2004
Employees
4.77K
Website
https://www.evotec.comCEO
Christian Wojczewski
Description
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
EVO Financial Timeline
Browse a chronological timeline of Evotec SE corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Nov 2025
Earnings released on 13 Aug 2025
EPS came in at -$0.29 falling short of the estimated -$0.18 by -60.14%, while revenue for the quarter reached $201.62M , beating expectations by +3.72%.
Earnings released on 6 May 2025
EPS came in at -$0.19 falling short of the estimated -$0.11 by -77.26%, while revenue for the quarter reached $219.23M , missing expectations by -20.54%.
Earnings released on 17 Apr 2025
EPS came in at -$0.12 falling short of the estimated $0.02 by -768.15%, while revenue for the quarter reached $229.08M , beating expectations by +11.58%.
Earnings released on 6 Nov 2024
EPS came in at -$0.12 falling short of the estimated -$0.08 by -50.00%, while revenue for the quarter reached $202.77M , missing expectations by -8.28%.
Earnings released on 14 Aug 2024
EPS came in at -$0.29 falling short of the estimated -$0.09 by -222.22%, while revenue for the quarter reached $195.83M , missing expectations by -11.58%.
Earnings released on 22 May 2024
EPS came in at -$0.05 falling short of the estimated -$0.03 by -49.52%, while revenue for the quarter reached $224.23M , missing expectations by -0.04%.
Earnings released on 26 Feb 2024
EPS came in at -$0.05 falling short of the estimated -$0.03 by -66.67%, while revenue for the quarter reached $221.40M .
Earnings released on 8 Nov 2023
EPS came in at -$0.12 falling short of the estimated -$0.05 by -140.00%, while revenue for the quarter reached $207.04M , beating expectations by +1.46%.
Earnings released on 29 Aug 2023
EPS came in at -$0.04 falling short of the estimated -$0.04 by -10.93%, while revenue for the quarter reached $185.76M , missing expectations by -13.54%.
Earnings released on 12 May 2023
EPS came in at -$0.08 falling short of the estimated $0.10 by -180.00%, while revenue for the quarter reached $232.18M .
Earnings released on 29 Mar 2023
EPS came in at -$0.13 falling short of the estimated $0.10 by -230.00%, while revenue for the quarter reached $259.26M , beating expectations by +9.63%.
Earnings released on 9 Nov 2022
EPS came in at -$0.26 falling short of the estimated $0.08 by -419.52%, while revenue for the quarter reached $169.81M , missing expectations by -6.89%.
Earnings released on 11 Aug 2022
EPS came in at -$0.08 falling short of the estimated -$0.02 by -375.06%, while revenue for the quarter reached $180.13M , beating expectations by +1.40%.
Earnings released on 11 May 2022
EPS came in at -$0.23 falling short of the estimated $0.06 by -483.33%, while revenue for the quarter reached $182.15M , beating expectations by +6.40%.
Earnings released on 12 Apr 2022
EPS came in at -$0.11 falling short of the estimated $0.07 by -257.14%, while revenue for the quarter reached $212.08M , beating expectations by +13.15%.
Earnings released on 11 Nov 2021
EPS came in at $0.95 , while revenue for the quarter reached $185.32M , missing expectations by -11.64%.
Stock split effective on 20 Oct 2021
Shares were split 4 : 1 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 Aug 2021
EPS came in at $0.43 , while revenue for the quarter reached $163.99M .
Earnings released on 11 May 2021
EPS came in at $0.38 , while revenue for the quarter reached $156.53M .
Earnings released on 25 Mar 2021
EPS came in at $0.00 , while revenue for the quarter reached $172.32M .
Earnings released on 12 Nov 2020
EPS came in at -$0.01 , while revenue for the quarter reached $151.96M .
EVO Stock Performance
Access detailed EVO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.